Patents by Inventor Sun Ah Jun
Sun Ah Jun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220389010Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: in Chemical Formula 1, R1 to R3 are as defined in the present specification.Type: ApplicationFiled: November 25, 2020Publication date: December 8, 2022Inventors: Ji Duck Kim, Sun Ah Jun, Nam Youn Kim, In Woo Kim, Hyae Jung Hyun, Joon Seok Park
-
Patent number: 11339167Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: wherein: R1 is pyrazolyl, isooxazolyl, isothiazolyl, phenyl, or benzothiazolyl, wherein the pyrazolyl, isoxazolyl, isothiazolyl, phenyl, or benzothiazolyl is optionally substituted with one Ra substituent; R2 is H, halogen, CN, or C1-5 alkyl; and Ra is C1-5 alkyl, C1-5 haloalkyl, C1-5 hydroxyalkyl, C3-6 cycloalkyl, tetrahydropyranyl, piperidinyl, or morpholino.Type: GrantFiled: December 28, 2018Date of Patent: May 24, 2022Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: In Woo Kim, Sun Ah Jun, Nam Youn Kim, Jun Hee Lee
-
Patent number: 11084823Abstract: The present invention relates to a compound represented by the Chemical Formula 1 defined in the present specification, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.Type: GrantFiled: March 19, 2018Date of Patent: August 10, 2021Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: In Woo Kim, Ja Kyung Yoo, Ji Duck Kim, Sun Ah Jun, Jun Hee Lee
-
Publication number: 20210130358Abstract: The present invention relates to a compound represented by the Chemical Formula 1 defined in the present specification, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.Type: ApplicationFiled: March 19, 2018Publication date: May 6, 2021Inventors: In Woo Kim, Ja Kyung Yoo, Ji Duck Kim, Sun Ah Jun, Jun Hee Lee
-
Patent number: 10961247Abstract: The present invention relates to a pyrazolopyrimidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.Type: GrantFiled: June 30, 2017Date of Patent: March 30, 2021Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: In Woo Kim, Mi Ryeong Han, Jakyung Yoo, Yun Ju Oh, Ji Duck Kim, Nam Youn Kim, Sun Ah Jun, Jun Hee Lee, Joon Seok Park
-
Publication number: 20200317673Abstract: The present invention relates to a pyrazolopyrimidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.Type: ApplicationFiled: June 30, 2017Publication date: October 8, 2020Inventors: In Woo Kim, Mi Ryeong Han, Jakyung Yoo, Yun Ju Oh, Ji Duck Kim, Nam Youn Kim, Sun Ah Jun, Jun Hee Lee, Joon Seok Park
-
Publication number: 20200308177Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatm ent of diseases which are associated with kinase inhibitory actions.Type: ApplicationFiled: December 28, 2018Publication date: October 1, 2020Inventors: In Woo Kim, Sun Ah Jun, Nam Youn Kim, Jun Hee Lee
-
Patent number: 10590078Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).Type: GrantFiled: February 11, 2016Date of Patent: March 17, 2020Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ji Duck Kim, Hyung Geun Lee, Inwoo Kim, Sun Ah Jun, Myunggi Jung, Hyo Shin Kim
-
Patent number: 10227338Abstract: The invention relates to a compound represented by Chemical Formula 1, below, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound or salt. The compound of the invention or pharmaceutically acceptable salts thereof can be used for the prevention or treatment of sodium channel blocker-related diseases.Type: GrantFiled: November 11, 2016Date of Patent: March 12, 2019Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Hyung-Geun Lee, Il-Hwan Kim, Myunggi Jung, Hyo Shin Kim, Chun Ho Lee, Sun Ah Jun, Ji Sung Yoon, Sung-Young Kim
-
Publication number: 20180346459Abstract: The present invention relates to a compound represented by Chemical Formula, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of sodium channel blocker-related diseases.Type: ApplicationFiled: November 11, 2016Publication date: December 6, 2018Inventors: Hyung-Geun LEE, Il-Hwan KIM, Myunggi JUNG, Hyo Shin KIM, Chun Ho LEE, Sun Ah JUN, Ji Sung YOON, Sung-Young KIM
-
Publication number: 20180297948Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).Type: ApplicationFiled: February 11, 2016Publication date: October 18, 2018Inventors: Ji Duck KIM, Hyung Geun LEE, Inwoo KIM, Sun Ah JUN, Myunggi JUNG, Hyo Shin KIM
-
Patent number: 9376429Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and the use thereof. A compound represented by formula 1 according to the invention, or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof may be effectively used for the prevention or treatment of pain, for example, acute pain, chronic pain, neuropathic pain, post-surgery pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, or paroxysmal extreme pain disorder (PEPD).Type: GrantFiled: October 15, 2013Date of Patent: June 28, 2016Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ha Young Kim, In Woo Kim, Sun Ah Jun, Yun Soo Na, Hyung Geun Lee, Min Jae Cho, Jun Hee Lee, Hyo Shin Kim, Yun Soo Yoon, Kyung Ha Chung, Ji Duck Kim
-
Patent number: 9328115Abstract: Provided is a process for the preparation of meropenem trihydrate in high purity and high yield, including using a dry methanol solvate of meropenem, which can remarkably reduce the amount of residual solvents in the resulting product, thereby obtain meropenem trihydrate in high purity.Type: GrantFiled: November 21, 2013Date of Patent: May 3, 2016Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: Soo-Jin Choi, Byung-Goo Lee, Hee-Kyoon Yoon, Sung-Woo Park, Sun-Ah Jun, Kyung-Ho Lee, Byung-Jo Lim
-
Patent number: 9233963Abstract: The present invention relates to an improved method for synthesizing meropenem trihydrate[(1R,5S,6S)-2-[((2?S,4?S)-2?-dimethylaminocarbozyl)pyrrolidin-4?-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid, trihydrate], which is a novel carbapenem antibiotic.Type: GrantFiled: March 11, 2010Date of Patent: January 12, 2016Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., DAEWOONG BIO, INC.Inventors: Yoon Seok Song, Sung Woo Park, Yeon Jung Yoon, Hee Kyoon Yoon, Seong Cheol Moon, Byung Goo Lee, Soo Jin Choi, Sun Ah Jun
-
Publication number: 20150353554Abstract: Provided is a process for the preparation of meropenem trihydrate in high purity and high yield, including using a dry methanol solvate of meropenem, which can remarkably reduce the amount of residual solvents in the resulting product, thereby obtain meropenem trihydrate in high purity.Type: ApplicationFiled: November 21, 2013Publication date: December 10, 2015Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: Soo-Jin CHOI, Byung-Goo LEE, Hee-Kyoon YOON, Sung-Woo PARK, Sun-Ah JUN, Kyung-Ho LEE, Byung-Jo LIM
-
Publication number: 20150336944Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and the use thereof. A compound represented by formula 1 according to the invention, or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof may be effectively used for the prevention or treatment of pain, for example, acute pain, chronic pain, neuropathic pain, post-surgery pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, or paroxysmal extreme pain disorder (PEPD).Type: ApplicationFiled: October 15, 2013Publication date: November 26, 2015Inventors: Ha Young Kim, In Woo Kim, Sun Ah Jun, Yun Soo Na, Hyung Geun Lee, Min Jae Cho, Jun Hee Lee, Hyo Shin Kim, Yun Soo Yoon, Kyung Ha Chung, Ji Duck Kim
-
Publication number: 20120065392Abstract: The present invention relates to an improved method for synthesizing meropenem trihydrate [(1R,5S,6S)-2-[((2?S,4?S)-2?-dimethylaminocarbozyl)pyrrolidin-4?-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid, trihydrate], which is a novel carbapenem antibiotic.Type: ApplicationFiled: March 11, 2010Publication date: March 15, 2012Applicants: DAEWOONG BIO INC., DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: Yoon Seok Song, Sung Woo Park, Yeon Jung Yoon, Hee Kyoon Yoon, Seong Cheol Moon, Byung Goo Lee, Soo Jin Choi, Sun Ah Jun